Caplin Point’s Puducherry Unit-1 Receives INVIMA Nod for Softgel Capsules Division

On May 6, 2024, Caplin Point Laboratories Limited informed the stock exchanges that Colombia’s INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA) approved the company’s Softgel Capsules division at Puducherry, Tamil Nadu.

Caplin Point Laboratories stated that on May 3, 2024, the site inspection of Unit-1 was done and found compliant with INVlMA’s norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).

The Unit currently caters to emerging markets in Africa and Latin America with various dosage forms, including capsules, tablets, liquid orals, soft gel capsules, topicals, suppositories, and injectables.

Speaking on the approval, the Chairman of Caplin Point Laboratories Limited, Mr C.C.Paarthipan, said, “Expansion into larger markets of Latin America, such as Colombia, is an important aspect of our future growth, and this approval, especially in the niche Softgel Capsules range will contribute well to the same.”

In April 2024, the company’s subsidiary, Caplin Steriles Limited (Caplin), was granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution USP 0.3%, which is a generic therapeutic equivalent version of (RLD), OCUFLOX Ophthalmic Solution of Allergan Inc. The company stated that Ofloxacin Ophthalmic Solution USP 0.3% is prescribed to treat eye infections caused by the conditions of conjunctivitis and corneal ulcers.

Prior to that, in March, Caplin Steriles Limited got approval from the US FDA for its ANDA Ketorolac tromethamine Ophthalmic Solution 0.5% (eye drops), a generic therapeutic equivalent version of (RLD), ACULAR Ophthalmic Solution of Allergan Inc.

About Caplin Point Laboratories Limited

Caplin Point Laboratories is a pharmaceutical company that caters primarily to the emerging markets of Africa and Latin America. The company has state-of-the-art manufacturing units that offer a wide range of finished dosage forms.

On May 6, 2024, the share price of Caplin Point Laboratories Ltd opened at ₹1,300.00, touching the day’s high at ₹1,324.45, as of 11:43 AM on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.